Alaunos Therapeutics, Inc.
TCRT
$4.29
$0.2947.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -50.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -50.00% | -- | |||
| Cost of Revenue | 102.33% | -160.14% | |||
| Gross Profit | -100.00% | 162.94% | |||
| SG&A Expenses | -11.60% | -16.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 44.14% | -34.00% | |||
| Operating Income | -44.64% | 34.35% | |||
| Income Before Tax | -44.61% | 34.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -44.61% | 34.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -44.61% | 34.16% | |||
| EBIT | -44.64% | 34.35% | |||
| EBITDA | -44.67% | 34.39% | |||
| EPS Basic | -44.61% | 34.16% | |||
| Normalized Basic EPS | -44.61% | 34.17% | |||
| EPS Diluted | -44.61% | 34.16% | |||
| Normalized Diluted EPS | -44.61% | 34.17% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||